STAT Plus: Johnson & Johnson partners with Celsius Therapeutics in large-scale test of single-cell sequencing
Celsius Therapeutics, a startup built around sequencing genetic material in thousands of an individual’s cells, announced a new deal with Janssen, Johnson and Johnson’s biotech subsidiary, on Tuesday — a partnership that will be the largest proving ground yet for single-cell RNA sequencing technology.
The partnership — for which financial terms were not disclosed — will give Celsius the chance to test its technology with a far bigger dataset than any company has ever used before. The sheer scale could put a renewed spotlight on single-cell RNA sequencing, which scientists hope could bring about more detailed and precise pictures of how individual genes in individual cells misbehave in a particular condition.
Continue to STAT Plus to read the full story…
